Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Granulomatosis With Polyangiitis Treatment Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The granulomatosis with polyangiitis treatment market has witnessed significant expansion in recent years. It is projected to increase from $2.55 billion in 2025 to $2.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. This historical growth can be attributed to several factors including the recognition of autoimmune diseases, the availability of corticosteroids, the provision of hospital nephrology services, the use of immunosuppressive drugs, and the adoption of diagnostic imaging.
The market for granulomatosis with polyangiitis treatments is anticipated to experience substantial expansion in the coming years. By 2030, this market is projected to reach a value of $3.69 billion, demonstrating a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this projected growth include advancements in biologic drugs, the development of precision autoimmune therapies, the availability of early diagnostic screening methods, increased demand for chronic disease management, and the expansion of specialty clinics. Key trends expected during the forecast period involve a greater adoption of biologic therapies, an increasing need for prompt autoimmune diagnosis, the development of strategies for long-term disease remission, an increase in combination immunosuppressive treatments, and enhanced monitoring of organ damage.
Get A Free Sample Report With In-Depth Market Insights:
Granulomatosis With Polyangiitis Treatment Market Development Factors: What’s Supporting Demand?
The rising occurrence of autoimmune conditions is anticipated to fuel the expansion of the granulomatosis with polyangiitis treatment market in the future. Autoimmune diseases develop when the body’s immune system erroneously targets its own healthy cells and tissues, resulting in inflammation and harm across various organs. The growing incidence of autoimmune diseases stems from environmental factors (like infections, chemicals, or pollutants) and shifts in lifestyle. Granulomatosis with polyangiitis treatment assists in managing autoimmune diseases through the application of immunosuppressive treatments, including corticosteroids and cyclophosphamide, which are effective in moderating inflammation and averting organ damage. This makes timely intervention and personalized therapy vital for addressing other autoimmune disorders with similar pathological processes. For instance, in June 2023, according to a report published by the Office for National Statistics, a UK-based government department, the global population of people with multiple sclerosis (MS) (an autoimmune disease) in 2023 was 2.9 million, up from 2.8 million in 2022. Consequently, the increasing prevalence of autoimmune diseases is stimulating the growth of the granulomatosis with polyangiitis treatment market.
Granulomatosis With Polyangiitis Treatment Market Segmentation: How Does The Market Break Down By Category?
The granulomatosis with polyangiitis treatment market covered in this report is segmented –
1) By Drug Type: Steroids, Immunosuppressants, Other Drug Types
2) By Route Of Administration: Oral, Intravenous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Steroids: Prednisone, Methylprednisolone, Dexamethasone, Hydrocortisone
2) By Immunosuppressants: Cyclophosphamide, Methotrexate, Azathioprine, Mycophenolate mofetil, Rituximab
3) By Other Drug Types: Plasma Exchange Therapy, Intravenous Immunoglobulin (IVIG), Biologic Agents, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Granulomatosis With Polyangiitis Treatment Market Trends Powering Strategic Industry Growth
Major companies in the granulomatosis with polyangiitis treatment market are focusing on developing innovative products, such as oral corticosteroids, to offer patients more effective treatment options that improve disease management while minimizing the long-term side effects of steroid use. Oral corticosteroids are a medication designed to reduce inflammation and suppress the immune system. They are commonly employed to treat allergies, autoimmune diseases, and inflammatory disorders. For instance, in October 2024, AstraZeneca plc, a UK-based pharmaceutical company, announced that Fasenra (bevacizumab) had received approval in the European Union, a Europe-based political and economic union of European countries, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This approval follows positive results from the MANDARA Phase III trial, which demonstrated Fasenra’s efficacy in achieving remission and reducing reliance on oral corticosteroids in EGPA patients.
Granulomatosis With Polyangiitis Treatment Market Competitive Overview And Top Companies
Major companies operating in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F Hoffmann La Roche Ltd, Sanofi S A, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, ChemoCentryx Inc, Medac Pharma Inc, InflaRx GmbH, AbbVie Inc, Johnson & Johnson, Bristol Myers Squibb Company, Novartis AG, Biogen Inc, Takeda Pharmaceutical Company Limited, UCB S A, Bayer AG, Merck & Co Inc, Eli Lilly and Company, Astellas Pharma Inc
View The Full Granulomatosis With Polyangiitis Treatment Market Report:
Granulomatosis With Polyangiitis Treatment Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the granulomatosis with polyangiitis treatment market in 2025. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
